- Home
- PNI vs ELTX Comparison
PNI vs ELTX Comparison
Compare PNI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | ELTX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.8M | 63.3M |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PNI | ELTX |
|---|---|---|
| Price | $6.12 | $1.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 89.0K | ★ 335.3K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.07 | $1.71 |
| 52 Week High | $7.20 | $16.00 |
Technical Indicators
Market Signals| Indicator | PNI | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 14.81 | 29.27 |
| Support Level | N/A | $1.71 |
| Resistance Level | $7.10 | $3.32 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 2.33 | 41.27 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.